Results are out: https://investor.lilly.com/events.cfm...

Results are out:
https://investor.lilly.com/events.cfm

https://investor.lilly.com/common/d...288CB1D2DF0C&filename=IR workbook Q4 2014.xls

Not bad - total Q4 net sales of US$47.6m and US$170.5m for the full year (inc international)
That is 31% up on Q3, but down QonQ.  
US market came in at US$163m net sales which is only down -7.5% on last year - not to bad given all the bad PR around the FDA stuff
International is up c.320% from US$1.6m in 2013 to US$6.7m 30124
So combined 2014 came in c.US$171m  vs US$178m 2013 - 4.6% down - hardly a disaster here.

The tail wind for ACR here is fx - 15% to 20% decline in the AUD... royalties are paid in USD so should give them a good earnings kick.  

Regards,

Mita